Sign up USA
Proactive Investors - Run By Investors For Investors

TheraLase Technologies treats third patient with lead cancer compound

The procedure sees Theralase's lead anti-cancer compound put through the urethra into the bladder
TheraLase Technologies treats third patient with lead cancer compound
Theralase is progressing its TLD-1433 clinical study

Theralase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) told investors a third patient had been treated with its photo dynamic therapy (PDT) treatment for bladder cancer.

The procedure sees Theralase's lead anti-cancer compound put through the urethra into the bladder.

The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water.

It is part of the Phase Ib NMIBC clinical study to evaluate the group's lead cancer compound TLD-1433 for the primary endpoints of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.

The study is designed to treat three patients at a lower dose and to monitor them for 30 day. If deemed successful, a further six patients will be enrolled to be treated at a higher dose and be monitored for 180 days.

By the end of May , an independent Data and Safety Monitoring Board will recommend on whether to enroll six additional patients for PDT dose escalation.

Theralase's chief Roger Dumoulin-White, said: "Theralase has now completed PDT treatment of the first 3 patients in the study and we look forward to successfully reporting out on our performance to the primary and secondary endpoints of the first three patients by the end of May 2017."

Shares in Toronto were unchanged at $0.425 each.

Giles_55af4ddca6481.jpg
Why Invest In Theralase Technologies Inc.? Read More Here

Register here to be notified of future TLT Company articles
View full TLT profile View Profile

Theralase Technologies Inc. Timeline

Related Articles

pioneering_tech_-__smart_burner_-_woman_hands_fire.png
May 17 2017
In 2016, Pioneering's market capitalization increased by 1,170% and its share price appreciated by 725%.
UUV-Aquabotix_Hybrid-and-Endura-pic-757.jpg
Sun
Brendan Martin talked underwater drone technology and commercialisation.
Investment-management.jpg
December 23 2016
Growth in the coming months will be achieved via a mix of well-judged acquisitions and getting the most from what it currently owns or has recently bought, the company said.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use